[go: up one dir, main page]

PE20120343A1 - Anticuerpo anti-cmet que comprende una region bisagra - Google Patents

Anticuerpo anti-cmet que comprende una region bisagra

Info

Publication number
PE20120343A1
PE20120343A1 PE2011001117A PE2011001117A PE20120343A1 PE 20120343 A1 PE20120343 A1 PE 20120343A1 PE 2011001117 A PE2011001117 A PE 2011001117A PE 2011001117 A PE2011001117 A PE 2011001117A PE 20120343 A1 PE20120343 A1 PE 20120343A1
Authority
PE
Peru
Prior art keywords
seq
cdr
receptor
hinged region
antibody including
Prior art date
Application number
PE2011001117A
Other languages
English (en)
Inventor
Liliane Goetsch
Thierry Wurch
Cedric Bes
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41693124&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120343(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/IB2008/055663 external-priority patent/WO2010064089A1/en
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of PE20120343A1 publication Critical patent/PE20120343A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Connection Of Motors, Electrical Generators, Mechanical Devices, And The Like (AREA)

Abstract

REFERIDA A UN ANTICUERPO MONOCLONAL, O SU FRAGMENTO O DERIVADO FUNCIONAL DIVALENTE, CAPAZ DE INHIBIR LA DIMERIZACION DE c-MET, QUE COMPRENDE: A) UNA CADENA PESADA QUE COMPRENDE CDR-H1 (SEC ID NO:1), CDR-H2 (SEC ID NO:2), CDR-H3 (SEC ID NO: 3); B) UNA CADENA LIGERA QUE COMPRENDE CDR-L1 (SEC ID NO: 5), CDR-L2 (SEC ID NO:6), CDR-L3 (SEC ID:7); Y C) UNA REGION BISAGRA QUE COMPRENDE LAS SECUENCIAS DE AMINOACIODS SELECCIONADA DE SEC ID NO: 22 A 28 Y SEC ID NO:72 A 86. DICHO ANTICUERPO SE UNE ESPECIFICAMENTE AL RECEPTOR C-MET HUMANO, INHIBIENDO ESPECIFICAMENTE LA ACTIVIDAD DE TIROSINA QUINASA DE DICHO RECEPTOR SIENDO UTIL EN EL TRATAMIENTO DE CANCER Y CUALQUIER PATOLOGIA RELACIONADA CON LA SOBREEXPRESION DE DICHO RECEPTOR
PE2011001117A 2008-12-02 2009-12-02 Anticuerpo anti-cmet que comprende una region bisagra PE20120343A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB2008/055663 WO2010064089A1 (en) 2008-12-02 2008-12-02 Novel anti-cmet antibody
US18450209P 2009-06-05 2009-06-05

Publications (1)

Publication Number Publication Date
PE20120343A1 true PE20120343A1 (es) 2012-04-16

Family

ID=41693124

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001117A PE20120343A1 (es) 2008-12-02 2009-12-02 Anticuerpo anti-cmet que comprende una region bisagra

Country Status (38)

Country Link
US (4) US8741290B2 (es)
EP (4) EP3135691B1 (es)
JP (3) JP5863458B2 (es)
KR (1) KR101838299B1 (es)
CN (2) CN102227446B (es)
AR (1) AR074439A1 (es)
AU (3) AU2009328318C1 (es)
BR (2) BRPI0923231B8 (es)
CA (1) CA2743433C (es)
CL (2) CL2011001296A1 (es)
CO (1) CO6382139A2 (es)
CR (1) CR20110324A (es)
CY (2) CY1119172T1 (es)
DK (2) DK3135691T3 (es)
EC (1) ECSP11011127A (es)
ES (3) ES2629855T3 (es)
GE (2) GEP20146207B (es)
HR (2) HRP20171011T8 (es)
HU (3) HUE051288T2 (es)
IL (2) IL213273A0 (es)
LT (2) LT3135691T (es)
MA (1) MA32892B1 (es)
MX (2) MX2011005677A (es)
MY (2) MY185200A (es)
NZ (1) NZ593853A (es)
PE (1) PE20120343A1 (es)
PH (1) PH12015501515A1 (es)
PL (3) PL3431502T3 (es)
PT (3) PT2370468T (es)
RS (2) RS58018B1 (es)
RU (2) RU2560257C2 (es)
SA (2) SA109300720B1 (es)
SG (2) SG187518A1 (es)
SI (3) SI3135691T1 (es)
TN (1) TN2011000216A1 (es)
TW (2) TWI523866B (es)
WO (1) WO2010069765A1 (es)
ZA (1) ZA201105164B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
US9068011B2 (en) 2010-03-10 2015-06-30 Genmab A+S Monoclonal antibodies against c-Met
AU2011296085A1 (en) 2010-09-03 2013-03-28 Academia Sinica Anti-c-Met antibody and methods of use thereof
WO2012059562A1 (en) 2010-11-03 2012-05-10 Argen-X-Bv C-met antibody combinations
EP2710042A2 (en) 2011-05-16 2014-03-26 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
KR101865223B1 (ko) 2011-10-05 2018-06-08 삼성전자주식회사 항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도
KR20130036993A (ko) * 2011-10-05 2013-04-15 삼성전자주식회사 ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
WO2013064700A2 (en) 2011-11-03 2013-05-10 Argen-X B.V. Chimeric polypeptides and methods of use
KR101463098B1 (ko) 2011-11-28 2014-11-27 한국생명공학연구원 ｃ-Ｍｅｔ에 대한 인간항체에 약물이 접합된 약물 복합체 및 이의 용도
KR101910601B1 (ko) 2011-12-22 2018-10-23 삼성전자주식회사 면역원성이 제거된 항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도
CA2877573A1 (en) * 2012-06-21 2013-12-27 Sorrento Therapeutics, Inc. Antigen binding proteins that bind c-met
US9931400B2 (en) 2012-09-12 2018-04-03 Samsung Electronics Co., Ltd. Method of combination therapy for prevention or treatment of c-Met or angiogenesis factor induced diseases
ES2530968T3 (es) 2012-10-12 2015-03-09 Spirogen Sarl Pirrolobenzodiazepinas y conjugados de las mismas
WO2014140174A1 (en) 2013-03-13 2014-09-18 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
KR102049990B1 (ko) * 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
US9994644B2 (en) 2013-04-30 2018-06-12 Agency For Science, Technology And Research mAB 2 anti-Met antibody
US9567641B2 (en) * 2013-07-03 2017-02-14 Samsung Electronics Co., Ltd. Combination therapy for the treatment of cancer using an anti-C-met antibody
US9717715B2 (en) 2013-11-15 2017-08-01 Samsung Electronics Co., Ltd. Method of combination therapy using an anti-C-Met antibody
RU2656153C1 (ru) * 2013-12-20 2018-05-31 Девелопмент Сентер Фор Байотекнолоджи Антитела, специфичные к альфа-энолазе, и способы применения в противоопухолевой терапии
JP6531166B2 (ja) 2014-09-10 2019-06-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
EP3270918A4 (en) * 2015-03-16 2018-10-24 Celldex Therapeutics, Inc. Anti-met antibodies and methods of use thereof
ES2896709T3 (es) * 2016-02-05 2022-02-25 Helixmith Co Ltd Anticuerpos anti-c-Met y usos de los mismos
CA3017776A1 (en) 2016-03-15 2017-09-21 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
NZ748314A (en) * 2016-05-17 2023-07-28 Abbvie Inc Anti-cmet antibody drug conjugates and methods for their use
US10457726B2 (en) 2016-06-30 2019-10-29 University Of Connecticut Antibody and antigen-binding fragment compositions targeting cell surface antigens in tumors and methods of use thereof
WO2018069289A1 (en) 2016-10-11 2018-04-19 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
RU2741228C2 (ru) * 2016-11-14 2021-01-22 Общество С Ограниченной Ответственностью "Панацела Лабс" Противоопухолевые эффекты вирусного вектора, кодирующего толл-подобный рецептор и агонист толл-подобного рецептора
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
WO2018129029A1 (en) * 2017-01-04 2018-07-12 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
CN109771642B (zh) 2017-11-13 2022-09-20 同济大学苏州研究院 c-MET激动型抗体及其用途
GB201803892D0 (en) * 2018-03-12 2018-04-25 Ultrahuman Six Ltd C-met binding agents
CN113286616A (zh) 2018-05-23 2021-08-20 Adc治疗有限公司 分子佐剂
AU2019318087B2 (en) * 2018-08-08 2025-09-18 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD 16 and a tumor-associated antigen
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
CN109541221B (zh) * 2018-10-24 2022-03-22 益善生物技术股份有限公司 一种c-Met特异性抗体、组合物及试剂盒
KR102353568B1 (ko) * 2018-11-14 2022-01-20 주식회사 헬릭스미스 안정성이 향상된 항 c-Met 항체 또는 그의 항원 결합 단편
WO2020198731A2 (en) * 2019-03-28 2020-10-01 Danisco Us Inc Engineered antibodies
MX2022002886A (es) 2019-09-16 2022-04-06 Regeneron Pharma Proteinas de union met radiomarcadas para la obtencion de imagenes por inmuno-pet.
KR20230018454A (ko) 2020-09-01 2023-02-07 레메젠 코, 리미티드 항-c-Met 항체-약물 접합체 및 이의 용도
WO2022079211A1 (en) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
WO2022216796A1 (en) 2021-04-06 2022-10-13 Abbvie Biotherapeutics Inc. Methods of treatment of non-small-cell lung carcinoma using telisotuzumab vedotin
US20240376214A1 (en) * 2021-04-08 2024-11-14 Byondis B.V. Anti-c-met antibodies and antibody-drug conjugates
AR125473A1 (es) 2021-04-29 2023-07-19 Abbvie Inc Conjugados de anticuerpo anti-c-met y fármaco
EP4426727A2 (en) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
US20230285394A1 (en) 2022-03-11 2023-09-14 Abbvie Biotherapeutics Inc. Methods of treatment of non-small-cell lung carcinoma using telisotuzummab vedotin and osimertinib
WO2024243450A1 (en) 2023-05-23 2024-11-28 Abbvie Inc. Methods of treatment using anti-c-met antibody drug conjugates
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4424200A (en) 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4479930A (en) 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
WO2002055106A2 (en) * 2001-01-09 2002-07-18 Merck Patent Gmbh Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
WO2004072117A2 (en) * 2003-02-13 2004-08-26 Pharmacia Corporation Antibodies to c-met for the treatment of cancers
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
US20050233960A1 (en) 2003-12-11 2005-10-20 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
PT1773885E (pt) * 2004-08-05 2010-07-21 Genentech Inc Antagonistas anti-cmet humanizados
US8008443B2 (en) * 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
KR20130023356A (ko) * 2005-07-18 2013-03-07 메다렉스, 인코포레이티드 인간 항-ｂ7ｒｐ1 중화 항체
EP1913027B1 (en) * 2005-07-28 2015-03-04 Novartis AG M-csf specific monoclonal antibody and uses thereof
JP5536445B2 (ja) * 2006-03-30 2014-07-02 ノバルティス アーゲー ｃ−Ｍｅｔの抗体の組成物およびその使用方法
EP2014681A1 (en) * 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
US8545839B2 (en) 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody

Also Published As

Publication number Publication date
RU2011124751A (ru) 2013-01-10
BR122019023930B1 (pt) 2021-05-04
TWI459964B (zh) 2014-11-11
CN102227446A (zh) 2011-10-26
RU2560257C2 (ru) 2015-08-20
US20130109844A1 (en) 2013-05-02
DK2370468T3 (en) 2017-06-19
US8765128B2 (en) 2014-07-01
AU2016200725C1 (en) 2017-10-19
AU2017203929A1 (en) 2017-07-06
CN102227446B (zh) 2015-10-21
RS56204B1 (sr) 2017-11-30
JP5863458B2 (ja) 2016-02-16
PT3135691T (pt) 2018-11-27
MY185200A (en) 2021-04-30
KR20110097839A (ko) 2011-08-31
CA2743433A1 (en) 2010-06-24
AR074439A1 (es) 2011-01-19
JP6074018B2 (ja) 2017-02-01
IL231525A0 (en) 2014-04-30
CY1121025T1 (el) 2019-12-11
PH12015501515A1 (en) 2015-12-14
HK1162536A1 (zh) 2012-08-31
EP3431502A1 (en) 2019-01-23
PL3431502T3 (pl) 2020-12-28
RS58018B1 (sr) 2019-02-28
KR101838299B1 (ko) 2018-03-14
AU2009328318C1 (en) 2017-11-02
PT3431502T (pt) 2020-10-29
MX2011005677A (es) 2011-06-30
AU2009328318B2 (en) 2015-11-05
SA109300720B1 (ar) 2013-05-25
EP3135691A1 (en) 2017-03-01
US8729249B2 (en) 2014-05-20
SI2370468T1 (sl) 2017-08-31
CN103351438B (zh) 2016-04-20
US20110239316A1 (en) 2011-09-29
HK1190414A1 (zh) 2014-07-04
CL2014000181A1 (es) 2014-07-25
WO2010069765A1 (en) 2010-06-24
ES2697098T3 (es) 2019-01-22
MY192567A (en) 2022-08-29
HUE051288T2 (hu) 2021-03-01
BRPI0923231A2 (pt) 2016-01-26
EP3757132A1 (en) 2020-12-30
GEP20146207B (en) 2014-12-10
TW201023892A (en) 2010-07-01
CO6382139A2 (es) 2012-02-15
SA112331005B1 (ar) 2015-09-13
TWI523866B (zh) 2016-03-01
HRP20171011T8 (hr) 2019-01-25
IL213273A0 (en) 2011-07-31
ES2629855T3 (es) 2017-08-16
NZ593853A (en) 2013-03-28
US20130109841A1 (en) 2013-05-02
HRP20181868T1 (hr) 2019-01-11
JP2017099392A (ja) 2017-06-08
TW201446805A (zh) 2014-12-16
JP2012510280A (ja) 2012-05-10
US8741290B2 (en) 2014-06-03
ZA201105164B (en) 2012-03-28
US20130109840A1 (en) 2013-05-02
SI3431502T1 (sl) 2021-01-29
SG171851A1 (en) 2011-07-28
HUE035047T2 (en) 2018-05-02
SG187518A1 (en) 2013-02-28
IL231525B (en) 2019-07-31
EP2370468A1 (en) 2011-10-05
EP3135691B1 (en) 2018-08-15
AU2016200725A1 (en) 2016-02-25
PT2370468T (pt) 2017-07-13
AU2009328318A1 (en) 2011-07-28
ES2827277T3 (es) 2021-05-20
BRPI0923231B1 (pt) 2020-04-28
MA32892B1 (fr) 2011-12-01
TN2011000216A1 (en) 2012-12-17
CL2011001296A1 (es) 2011-08-26
BRPI0923231B8 (pt) 2021-05-25
PL2370468T3 (pl) 2017-09-29
US8747850B2 (en) 2014-06-10
EP3431502B1 (en) 2020-07-22
GEP20135930B (en) 2013-10-10
ECSP11011127A (es) 2011-07-29
EP2370468B1 (en) 2017-04-05
SI3135691T1 (sl) 2018-12-31
JP2016117721A (ja) 2016-06-30
MX341014B (es) 2016-08-03
LT3135691T (lt) 2018-11-12
CY1119172T1 (el) 2018-02-14
CR20110324A (es) 2011-07-28
PL3135691T3 (pl) 2019-02-28
CN103351438A (zh) 2013-10-16
AU2016200725B2 (en) 2017-05-25
DK3135691T3 (en) 2018-11-19
JP6309657B2 (ja) 2018-04-11
AU2017203929B2 (en) 2019-03-28
RU2015127471A (ru) 2018-12-21
LT2370468T (lt) 2017-07-10
HUE040553T2 (hu) 2019-03-28
CA2743433C (en) 2019-06-11
HRP20171011T1 (hr) 2017-09-22

Similar Documents

Publication Publication Date Title
PE20120343A1 (es) Anticuerpo anti-cmet que comprende una region bisagra
PE20211863A1 (es) Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap
UA108466C2 (en) Antibody antagonises c-Met
PE20110668A1 (es) Anticuerpos anti-linfopoyetina estromal timica (anti-tslp)
TW200720289A (en) Antibodies against CCR5 and uses thereof
RU2012154339A (ru) НОВОЕ АНТИТЕЛО ПРОТИВ c-Met
NZ700473A (en) Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof
NZ585559A (en) Humanized antibodies against tl1a
AR109535A2 (es) Anticuerpos inhibidores de la dimerización del c-met y usos de los mismos
NZ623319A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
NZ599683A (en) Anti-ilt7 antibody
PE20120079A1 (es) Moleculas de anticuerpos mejoradas
AR080501A1 (es) Anticuerpos anti factor determinante antigenico de la muerte programada 1 (anti-pd1)
NZ596712A (en) Anti cxcr4 antibodies for the treatment of hiv
PE20130580A1 (es) Proteinas terapeuticas de union a dll4
AR040046A1 (es) Anticuerpo neutralizante humano anti-igfr
MX2018014714A (es) Composiciones para inhibir la activacion del complemento dependiente de la masp-2.
EA032189B9 (ru) Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их
ES2572177T3 (es) Anticuerpos neutralizantes anti-B7RP1 humanos
PE20120622A1 (es) Anticuerpos anti-vegf y sus usos
PE20080214A1 (es) Moleculas de anticuerpo que se unen a la il-17 humana
NZ605980A (en) Anti-fap antibodies and methods of use
PE20120211A1 (es) Anticuerpos que tienen especificidad por ox40 humana
NZ592151A (en) Anti-igf antibodies
PE20141398A1 (es) Anticuerpos neutralizantes de citomegalovirus humano

Legal Events

Date Code Title Description
FG Grant, registration